Related content

Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists

By  

Current Medicinal Chemistry - Central Nervous System Agents, Vol. 1, Iss. 2, 2001-08 ,pp. : 171-199

Bentham Science Publishers

Access to resources Recommend Favorite

Investigation of HTR3C mutations for association with 5HT₃ receptor antagonist anti-emetic efficacy

By Ward Michael B   Kotasek Dusan   McKinnon Ross A  

Pharmacogenomics, Vol. 9, Iss. 8, 2008-08 ,pp. : 1027-1033

Future Medicine

Access to resources Recommend Favorite

DNA variation and psychopharmacology of the human serotonin receptor 1B(HTR1B) gene

By Sanders Alan R   Duan Jubao   Gejman Pablo V  

Pharmacogenomics, Vol. 3, Iss. 6, 2002-11 ,pp. : 745-762

Future Medicine

Access to resources Recommend Favorite

Alternative Viewpoint Against Breast Cancer Based on Selective Serotonin Receptors 5HTR3A and 5HTR2A Antagonists that can Mediate Apoptosis in MCF-7 Cell Line

By  

Current Drug Discovery Technologies, Vol. 12, Iss. 4, 2015-12 ,pp. : 240-249

Bentham Science Publishers

Access to resources Recommend Favorite

Synthesis and evaluation of cis-1-methyl-3-n-propyl-2,3,3a,4,5,9b-hexahydro-1H-benz[e]indoles for in vitro dopamine D 1 and D 2 receptor binding affinity

By Ghosh D.   Klein C.   Garner B.   Andersen P.   Crider A.  

European Journal of Medicinal Chemistry, Vol. 30, Iss. 12, 1995-01 ,pp. : 943-948

Elsevier

Access to resources Recommend Favorite